| Literature DB >> 21647311 |
Mohammed A Alshawsh1, Mahmood Ameen Abdulla, Salmah Ismail, Zahra A Amin.
Abstract
Orthosiphon stamineus as medicinal plant is commonly used in Malaysia for treatment of hepatitis and jaundice; in this study, the ethanol extracts were applied to evaluate the hepatoprotective effects in a thioacetamide-induced hepatotoxic model in Sprague Dawley rats. Five groups of adult rats were arranged as follows: Group 1 (normal control group), Group 2 Thioacetamide (TAA) as positive control (hepatotoxic group), Group 3 Silymarin as a well-known standard drug (hepatoprotective group), and Groups 4 and 5 as high and low dose (treatment groups). After 60-day treatment, all rats were sacrificed. The hepatotoxic group showed a coarse granulation on the liver surface when compared to the smooth aspect observed on the liver surface of the other groups. Histopathological study confirmed the result; moreover, there was a significant increase in serum liver biochemical parameters (ALT, AST, ALP, and Bilirubin) and the level of liver Malondialdehyde (MDA), accompanied by a significant decrease in the level of total protein and Albumin in the TAA control group when compared with that of the normal group. The high-dose treatment group (200 mg/kg) significantly restored the elevated liver function enzymes near to normal. This study revealed that 200 mg/kg extracts of O. stamineus exerted a hepatoprotective effect.Entities:
Year: 2011 PMID: 21647311 PMCID: PMC3106356 DOI: 10.1155/2011/103039
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The body, liver, and spleen weight of rats after two-month treatments.
| Animal group | Body weight (g) (BW) | Liver weight (g) (LW) | LW/BW (%) | Spleen weight (g) (SW) | SW/BW (%) |
|---|---|---|---|---|---|
| Normal control | 254.9 ± 28.69 | 6.71 ± 0.64 | 2.71 ± 0.18 | 0.47 ± 0.08 | 0.18 ± 0.02 |
| TAA control (hepatotoxic group) | 202.0 ± 19.10 | 11.00 ± 1.11∗a | 5.43 ± 0.17∗a | 0.52 ± 0.07 | 0.26 ± 0.03 |
| HD 200 mg/kg (treatment group) | 232.7 ± 16.12 | 10.43 ± 0.69 | 4.50 ± 0.19∗b | 0.54 ± 0.04 | 0.23 ± 0.01 |
| LD 100 mg/kg (treatment group) | 263.3 ± 8.53 | 10.43 ± 0.72 | 3.94 ± 0.16∗∗c | 0.55 ± 0.03 | 0.21 ± 0.01 |
| Silymarin 50 mg/kg (hepatoprotective group) | 257.0 ± 21.97 | 7.71 ± 2.78 | 2.94 ± 0.13∗∗c | 0.53 ± 0.07 | 0.20 ± 0.01 |
All values are expressed as mean ± S.E.M. Means with different superscripts are significantly different.
a P < .05 versus Normal control group, b P < .05 versus TAA control group, and c P < .01 versus TAA control group.
Effect of TAA, Silymarin, and O. stamineus ethanolic extract on biochemical parameters in thioacetamide-Induced liver cirrhosis rats.
| Animal group | ALT (IU/L) | AST (IU/L) | ALP (IU/L) | Bilirubin (mg/dl) | T.Protein (g/l) | Albumin (g/l) | MDA nmol/mL |
|---|---|---|---|---|---|---|---|
| Normal control | 64.9 ± 4.19a | 164.4 ± 10.74a | 109.6 ± 9.80a | 1.86 ± 0.1a | 74.3 ± 1.15a | 12.1 ± 0.51a | 38.7 ± 2.6a |
| TAA Control | 213.3 ± 25.98d | 372.6 ± 29.98d | 435.8 ± 29.78d | 8.7 ± 0.57d | 60.7 ± 0.97d | 8.3 ± 0.57d | 107.1 ± 3.7d |
| HD 200 mg/kg | 95.7 ± 9.35b | 228.6 ± 14.10b | 289.0 ± 14.23c | 4.8 ± 0.59b | 68.0 ± 2.06c | 11.1 ± 0.63c | 45.3 ± 3.5b |
| LD 100 mg/kg | 108.0 ± 11.15c | 253.4 ± 18.67c | 383.6 ± 20.89 | 6.4 ± 0.72c | 64.6 ± 1.29 | 9.3 ± 0.36 | 72.6 ± 3.9c |
| Silymarin 50 mg/kg | 70.4 ± 5.60b | 171.6 ± 10.19b | 139.4 ± 9.54b | 3.0 ± 0.31b | 70.9 ± 0.91b | 11.7 ± 0.68b | 40.3 ± 2.8b |
All values are expressed as mean ± S.E.M. of eight rats in each group. Values not sharing a common superscript differ significantly, *P < .05. ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, and MDA: malondialdehyde.
Figure 1Effect of TAA, Silymarin, and 200 mg/kg O. stamineus ethanolic extract on liver gross and histology in TAA-Induced liver cirrhosis rats after two-month treatments. Eight animals of each group were investigated.